Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2009.575 | A multicentre study on the seasonal variation of fetal non-syndromal structural anomalies and the association with environmental factors in Hong Kong | Prof. Lao Terence |
| 2010.192 | A multicentre study on the precalence of gestational diabetes mellitus among women referred for prenatal diagnosis with suspected fetal structural and chromosomal anomalies, and the relationship between the degree of glucose intolerance with the type and | Prof. Lao Terence |
| 2013.223 | A MULTICENTRE STUDY FOR THE EVALUATION OF EFFICACY AND SAFETY OF BUPRENORPHINE TRANSDERMAL PATCH (NORSPANｮ OR SOVENORｮ TRANSDERMAL PATCH)IN PATIENTS WITH NON-MALIGNANT PAIN OF MODERATE TO SEVERE INTENSITY DUE TO OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, LOWER BACK PAIN AND JOINT / MUSCLE PAIN, WHEN AN OPIOID IS NECESSARY FOR OBTAINING ADEQUATE ANALGESIA | Dr. CHAN Simon KC |
| 2021.478 | A multicentre retrospective study on the clinical and radiological features, and outcome of surgical treatment in Atypical Femoral Fractures in Hong Kong |
Prof. WONG Ronald Man Yeung 黃文揚 |
| 2020.138 | A MULTICENTRE RETROSPECTIVE STUDY -- CLINICAL OUTCOMES OF CONSERVATIVE AND SURGICAL TREATMENTS IN UROGENITAL PROLAPSE AND URINARY INCONTINENCE | Dr. CHEUNG Rachel Yau Kar |
| 2023.412 | A multicentre retrospective observational study to evaluate the association between the time lag of lens extraction after acute primary angle closure (APAC) and treatment outcomes | Dr. CHAN Poemen Pui Man |
| 2012.199 | A Multicentre Randomized Program to Compare the Effect of the Joint Asia Diabetes Evaluation (JADE, structured care) versus the DIAbetes MONitoring Database (DIAMOND, usual care) Programs in Type 2 Diabetic Patients in Asia Pacific Region | Prof. CHAN Juliana |
| 2014.443 | A MULTICENTRE RANDOMIZED PROGRAM BY USING A DIABETIC KIDNEY DISEASE (DKD) REGISTRY TO TREAT TO MULTIPLE TARGETS (TMT) (DKD-TMT) | Dr. TSANG Chiu Chi |
| 2014.441 | A MULTICENTRE RANDOMIZED PROGRAM BY USING A DIABETIC KIDNEY DISEASE (DKD) REGISTRY TO TREAT TO MULTIPLE TARGETS (TMT) (DKD-TMT) | Dr. LUK Andrea |
| 2013.609 | A MULTICENTRE RANDOMIZED PROGRAM BY USING A DIABETIC KIDNEY DISEASE (DKD) REGISTRY TO TREAT TO MULTIPLE TARGETS (TMT) (DKD-TMT) | Prof. CHAN Juliana |
| 2016.223 | A multicentre randomised double-blind, placebo-controlled trial of Chinese medicine and/or progesterone in women with threatened miscarriage - a trial centre in Hong Kong |
Dr. WANG Chi Chiu 黄志超 |
| 2002.436 | A Multicentre Phase III Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Patients | Prof. Sung Jao Yiu Joseph |
| 2023.247 | A multicentered, single-group Phase 2, exploratory, open-label study to investigate safety and effect of sparsentan in combination with sodium glucose cotransporter-2 (SGLT2) inhibition in the treatment of adult participants with Immunoglobulin A nephropathy (IgAN) |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2009.196 | A Multicentered, Controlled, Randomized Study to Evaluate and Compare the Rate of Parastomal Herniation After Permanent Stoma Formation With and Without Reinforcement With an Intraperitoneal Onlay Mesh (IPOM) | Doctor POON CHI MING |
| 2014.090 | A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)Treated with Enzalutamide Who Are at Potential Increased Risk of Seizure | Prof. NG Chi Fai |
| 2013.237 | A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma | Dr. CHAN Stephen L. |
| 2006.275 | A Multicenter, Randomized, Open-Label Comparison of the Safety and Efficacy of Tigecycline with That of Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Complicated Skin and Skin Structure Infections | Prof. Andrew Burd |
| 2006.157 | A Multicenter, Randomized, Open Label Dose Finding Study of RO0503821 in Anemic Patients with Stage IIIB or IV Non-Small Cell Lung Cancer Receiving First Line Myelosuppressive Chemotherapy | Prof. Mok Tony |
| 2009.218 | A Multicenter, Randomized, Doubled-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA-CER) | Professor Cheuk-Man YU |
| 2013.153 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF ALEGLITAZAR MONOTHERAPY COMPARED WITH PLACEBO IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2D) WHO ARE DRUG-NA_VE TO ANTIHYPERGLYCEMIC THERAPY | Prof. Kong Pik Shan |
| 2013.154 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF ALEGLITAZAR MONOTHERAPY COMPARED WITH PLACEBO IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2D) WHO ARE DRUG-NA_VE TO ANTIHYPERGLYCEMIC THERAPY | Dr. Tsang Chiu Chi |
| 2012.278 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects with Type 2 Diabetes and with Cardiovascular Disease or Multiple Risk Factors for Cardiovascular Events | Dr. TSANG Chiu Chi |
| 2012.332 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects with Type 2 Diabetes and with Cardiovascular Disease or Multiple Risk Factors for Cardiovascular Events | Prof. YU Cheuk Man |
| 2012.274 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects with Type 2 Diabetes and with Cardiovascular Disease or Multiple Risk Factors for Cardiovascular Events | Dr. CHOW Francis Chun-Chung |
| 2021.187 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Dapirolizumab pegol in Study Participants with Moderately to Severely Active Systemic Lupus Erythematosus |
Prof. TAM Lai Shan 譚麗珊 教授 |
| 2005.093 | A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety and Efficacy of Oral Dosing with GW679769 (50mg or 150mg) for Three Consecutive Days When Administered with a Single Intravenous Dose of Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting and Post-discharge Nausea and Vomiting in Female Subjects with Known Risk Factors for Post-operative Nausea and Vomiting Who are Undergoing Laparoscopic/Laparotomic Surgical Procedures Associated with an Increased Emetogenic Risk | Prof. Gin Tony |
| 2008.207 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group-Comparison Trial of Aripiprazole in the Treatment of Patients with Bipolar Disorder Experiencing a Manic Episode or Mixed Episode | Prof. Wing Yun Kwok |
| 2015.190 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination with Entecavir or Tenofovir in Patients with HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection |
Prof. CHAN Henry Lik Yuen 陳力元教授 |
| 2015.189 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination with Entecavir or Tenofovir in Patients with HBeAg Negative, Chronic Hepatitis B Virus (HBV) Infection |
Prof. CHAN Henry Lik Yuen 陳力元教授 |
| 2013.605 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After a Single Intravenous Dose of ARC-520 in Combination with Entecavir in Patients with Chronic Hepatitis B Virus (HBV) Infection, followed by a two-dose open label cohort and an open label single dose cohort in treatment naïve patients | Prof. CHAN Henry Lik Yuen |
| 2005.151 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 to Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Glimepiride Alone or in Combination with Metformin | Dr. So Wing Yee |
| 2008.216 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 | Prof. Yu Cheuk Man |
| 2012.007 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects With Lupus Nephritis | Prof. TAM Lai Shan |
| 2010.385 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes and Acute Coronary Syndrome | Dr Yan Ping Yen Bryan |
| 2010.270 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes and Acute Coronary Syndrome | Dr Chow Chun Chung, Francis |
| 2007.130 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Lipid-Altering Efficacy and Safety and Tolerability of MK-0524A in Patients with Primary Hypercholesterolemia or Mixed Hyperlipidemia | Dr. So Wing Yee |
| 2006.057 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination with Glyburide in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Glyburide Alone | Prof. Tong C.Y. Peter |
| 2010.030 | A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma | Dr. WONG Raymond Siu Ming |
| 2010.356 | A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib | Dr. Chan Lam Stephen |
| 2020.455 | A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥ 40% (LVEF ≥ 40%) |
Prof. LEE Pui Wai 李沛威 |
| 2010.440 | A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction | Associate Professor Yip Wai-Kwok , Gabriel |
| 2008.293 | A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK-0524B (dosed as coadministered MK-0524A and Simvastatin Tablets) Versus Atorvastatin in Patients With Mixed Hyperlipidemia | Dr. So Wing Yee |
| 2015.633 | A multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled study to evaluate the efficacy and safety of finerenone compared to eplerenone on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction after recent heart failure decompensation and additional risk factors, either type 2 diabetes mellitus or chronic kidney disease or both. |
Dr. LEE Alex Pui Wai 李沛威 |
| 2007.028 | A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, 8-Week Comparative Efficacy and Safety Study of Esomeprazole 20 mg qd Versus Ranitidine 150 mg bid in Patients with An NSAID-Associated Gastric Ulcer When Daily NSAID is Continued | Prof. Chan KL Francis |
| 2007.321 | A Multicenter, Randomized, Double-Blind, Controlled Phase 3, Efficacy and Safety Study of Sunitinib (SU011248) in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer Treated with Erlotinib | Prof. Mok S.K. Tony |
| 2009.411 | A multicenter, randomized, double-blind, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous idrabiotaparinux (SSR126517E) with oral adjusted-dose warfarin in the prevention of stroke and systemic thromboembolic events in patients with atrial fibrillation | Prof. WONG Lawrence Ka Sing |
| 2012.314 | A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Glimepiride When Used in Combination with Metformin in Subjects with Type 2 Diabetes | Prof. TOMLINSON Brian |
| 2012.329 | A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Glimepiride When Used in Combination with Metformin in Subjects with Type 2 Diabetes | Dr. OZAKI Risa |
| 2009.212 | A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide When Used in Combination with Metformin in Subjects with Type 2 Diabetes | Dr. Ozaki Risa |
| 2009.211 | A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide When Used in Combination with Metformin in Subjects with Type 2 Diabetes | Dr Tsang Chiu Chi |
Page 250 of 262.